Navigation Links
Simcere Pharmaceutical Group Appoints Dr. Peng Wang as Chief Scientific Officer
Date:5/19/2009

NANJING, China, May 19 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in China, announced today the appointment of Dr. Peng Wang as Chief Scientific Officer.

Dr. Wang will lead the company's R&D team in developing new products and innovative research projects. He will also participate in the strategic planning of the R&D department and manage domestic and international research collaborations.

Dr. Wang has two decades of experience in pharmaceutical R&D, most recently serving as Vice President of Discovery Biology at WuXi PharmaTech. Previously, Dr. Wang was a Research Fellow at Schering-Plough Research Institute where he worked for eighteen years with increasing responsibilities. Dr. Wang received his Ph.D. in Biochemistry from the University of Tokyo in 1990.

"As a recognized biopharmaceutical expert, Dr. Wang is well positioned to contribute to Simcere's strategic development in this area," commented Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group, "Simcere is committed to investing in research and development to support our long term growth, and we are delighted that Dr. Wang has agreed to join us."

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007
2. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
3. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
4. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
5. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
6. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
7. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
8. Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
9. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase
10. Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008
11. Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):